At the Inside 3D Printing Conference in Santa Clara, CA last week, Organovo CEO Keith Murphy gave a speech in which he presented his company's upcoming plans. Bioprinting is a huge potential application for 3D printing in the health industry. While 3D printing of a full organ is still a long way off, Murphy estimates that within the next 4-6 years Organovo will successfully begin clinical trials for the 3D printing of partial human livers. Use of these partial organs could extend patients' lives for up to a year while they wait for a donor liver to become available. If this application is successful, Organovo will set itself up for a huge future in bioprinting. Read more details in the full article:


Below is an image of a slide from Organovo's presentation, in which they addressed successful applications of 3D bioprinting in breast cancer research: